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Abstract
Microtubule associated protein tau (tau) deposition is associated with a spectrum of neurodegenerative diseases
collectively termed tauopathies. We have previously shown that amyotrophic lateral sclerosis (ALS) with cognitive
impairment (ALSci) is associated with tau phosphorylation at Thr175 and that this leads to activation of GSK3β which
then induces phosphorylation at tau Thr231. This latter step leads to dissociation of tau from microtubules and
pathological tau fibril formation. To determine the extent to which this pathway is unique to ALS, we have
investigated the expression of pThr175 tau and pThr231 tau across a range of frontotemporal degenerations.
Representative sections from the superior frontal cortex, anterior cingulate cortex (ACC), amygdala, hippocampal
formation, basal ganglia, and substantia nigra were selected from neuropathologically confirmed cases of
Alzheimer’s disease (AD; n = 3), vascular dementia (n = 2), frontotemporal lobar degeneration (FTLD; n = 4), ALS (n =
5), ALSci (n = 6), Parkinson’s disease (PD; n = 5), corticobasal degeneration (CBD; n = 2), diffuse Lewy body dementia
(DLBD; n = 2), mixed DLBD (n = 3), multisystem atrophy (MSA; n = 6) and Pick’s disease (n = 1) and three
neuropathologically-normal control groups aged 50–60 (n = 6), 60–70 (n = 6) and 70–80 (n = 8). Sections were
examined using a panel of phospho-tau antibodies (pSer208,210, pThr217, pThr175, pThr231, pSer202 and T22
(oligomeric tau)). Across diseases, phospho-tau load was most prominent in layers II/III of the entorhinal cortex,
amygdala and hippocampus. This is in contrast to the preferential deposition of phospho-tau in the ACC and
frontal cortex in ALSci. Controls showed pThr175 tau expression only in the 7th decade of life and only in the
presence of tau pathology and tau oligomers. With the exception of DLBD, we observed pThr175 co-localizing with
pThr231 in the same cell populations as T22 positivity. This suggests that this pathway may be a common
mechanism of toxicity across the tauopathies.
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Introduction
Microtubule associated protein tau (tau) is a cytoskeletal
stabilizing protein involved in microtubule maintenance,
fast axonal transport, and other physiological functions in
neurons. Tau protein deposition is a characteristic of many
neurodegenerative diseases that are collectively referred to
as tauopathies. It has been shown that pathological species
of tau protein are abnormally phosphorylated at multiple
residues [1] and that this is linked to a decrease in tau’s
ability to bind to and stabilize microtubules [2, 3] with ac-
companying cytotoxicity [4]. While the isoform compos-
ition of insoluble tau deposits and the structural formation
of the protein aggregates differs amongst the tauopathies,
there are several phosphorylation sites that are thought to
be universally important in the induction of a tauopathy.
One potentially important phosphorylation site that has
gone relatively unstudied is threonine175 (Thr175). First
identified in Alzheimer’s disease as a unique phosphoepi-
tope [5], it was then determined that this site could be
phosphorylated by multiple kinases linked to tau protein
pathology, including GSK3β, JNK, ERK2, and p38 [6].
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pThr175 tau was then identified in amyotrophic lateral scler-
osis with cognitive impairment (ALSci) [7] and character-
ized in further detail in the context of this disease [8–12].
Importantly, pThr175 tau has been shown to induce tau fi-
bril formation and cell death in vitro [13]. Unlike other
widely accepted pathological phosphorylation sites on tau,
such as pThr231 and pSer202, pThr175 has not been observed
in the fetal brain where tau protein is hyperphosphorylated
[14–16], suggesting that this site may be uniquely associ-
ated with pathological processes. pThr175 tau has been
shown to induce GSK3β activation in cell culture and may
therefore act as a destabilizing event resulting in enhanced
phosphorylation of tau at other residues, resulting in dis-
sociation from microtubules and neuronal toxicity [17]. In
order to understand the extent to which this pathway of
pThr175 mediated tau aggregate formation underlies a
broad range of tauopathies, we have used a panel of
phospho-specific antibodies to characterize tau protein
pathology with specific interest in the expression of pThr175
tau across a broad range of tauopathies.
Materials and methods
Diseases studied included Alzheimer’s (AD; 3 cases), vascu-
lar dementia (VD; 2 cases), ALS (5 cases), ALSci (6 cases),
dementia with Lewy Bodies (DLBD; 2 cases), DLBD with
mixed pathology (mDLBD; 3 cases including 2 with DLBD/
VD and 1 with DLBD/AD)), frontotemporal lobar dementia
(FTLD-TDP; 3 cases including one with a pathological
C9orf72 hexanucleotide expansion with Type B pathology;
a single case with Type A pathology and a single case with
Type B pathology, FTLD-Tau; 1 case with familial history
and no known mutations) [18], multiple system atrophy
(MSA; 6 cases), Parkinson’s disease (PD; 5 cases), Pick’s dis-
ease (1 case), and corticobasal degeneration (CBD; 2 cases)
(Table 1). The institutional research ethics board approved
the protocol and consent was given for use of all tissue used
in this study. All neuropathological diagnosis were per-
formed by a neuropathologist (RH, LCA) and conformed
to international neuropathological criteria [19–21]. For all
comparisons, we grouped the staining according to ALS (n
= 5), ALSci (n = 6), or other tauopathy (n = 22).
To assess the extent of pThr175 tau, pThr231 tau and
tau oligomer pathological inclusions as a function of
ageing, three groups of controls were studied, encom-
passing the 6th (n = 6), 7th (n = 6), and 8th (n = 8) decades
of life (Table 1). Hippocampal sections from each group
were stained for pThr175 tau, pThr231 tau and oligomeric
tau (T22). These cases have been previously character-
ized in a study examining age-dependant tau deposition
in the frontal and entorhinal cortices and were shown to
be free of neurodegenerative disease [22].
Five to six micrometer paraffin-embedded sections from
the superior frontal gyrus, anterior cingulate (ACC), hippo-
campus, entorhinal cortex, dentate gyrus, amygdala, basal
ganglia and substantia nigra were used for all immunohisto-
chemical analyses.
Cases were stained by haematoxylin and eosin (H&E)
and Gallyas silver stain for routine histological analysis and
overall pathology characterization. Immunohistochemistry
was conducted using a series of antibodies (Table 2) previ-
ously characterized in ALSci [12], consisting of PHF tau
(AT8; Thermo Fischer IL, Canada), pThr175 tau, pSer208,210
tau, pThr217 tau (antibodies generated and designed in
house [12], pThr175 commercially available through 21st
Century, MA, USA).
Antigen retrieval was conducted as necessary (Table 2).
Endogenous peroxidase was quenched with 3% hydrogen
peroxide (BDH Chemicals, VWR, On, Canada). Primary
antibody incubation was performed at 4 °C overnight in
blocking buffer (5% BSA, 0.3% Triton-X 100 in 1 X PBS).
After washing, secondary antibody (1:200 biotinylated IgG)
incubation was performed for 1 h at room temperature in
blocking buffer. Antigen:antibody complex was visualized
with either horseradish peroxidase or alkaline phosphatase
according to the manufacturer’s instructions (Vectastain
ABC kit, Vector Laboratories CA, USA), followed by sub-
strate development with either DAB plus NiCl2 or AP sub-
strate kit III (Vector Laboratories). Counterstaining was
performed using haematoxylin or nuclear fast red. The ex-
tent of pathology was described topographically and semi-
quantitatively as previously reported [12]. Representative
images were captured with a 20x lens under light micros-
copy (Olympus BX45) and subsequently used for semi-
Table 1 Case demographics
Neuropathological diagnosis Age n (n Male)
AD 72 ± 8 3 (2)
VD 78 ± 11 2 (1)
ALS 56 ± 16 5 (4)
ALSci 64 ± 11 6 (5)
DLBD 68 ± 1 2 (2)
mDLDB 83 ± 6 3 (3)
FTLD 64 ± 9 4 (1)
MSA 69 ± 12 6 (3)
PD 77 ± 2 5 (4)
Pick’s 70 ± 2 2 (2)
CBD 71 ± 1 2 (1)
Control 1 55 ± 2 6 (4)
Control 2 64 ± 2 6 (4)
Control 3 75 ± 3 8 (4)
AD Alzheimer’s disease, VD Vascular dementia, ALS amyotrophic lateral
sclerosis, ALSci ALS with cognitive impairment, DLBD diffuse Lewy body
dementia, mDLBD Lewy body dementia with mixed pathology, FTLD
frontotemporal lobar dementia, MSA multiple system atrophy, PD Parkinson’s
disease, Pick’s Pick’s disease, CBD corticobasal degeneration. Control 1: 6th
decade control group, Control 2: 7th decade control group, Control 3: 8th
decade control group
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quantitative analysis. The semi-quantitative scale was
manually applied for each type of pathology by an evaluator
blinded to the underlying diagnosis (WY) (neuronal, neur-
itic, or glial) separately as follows: ‘-’ = none; ‘±’ = less than 5
inclusions; ‘+’ = less than 10 inclusions; ‘++’ =more than 20
inclusions with scattered distribution; ‘+++’ =more than 20
inclusions but with locally dense distribution; ‘++++’ =
more than 20 inclusions with a diffuse distribution. Add-
itionally, the case positive ratio was defined for each anti-
body used and brain region investigated as the number of
cases showing any pathology (± or more) compared to the
total number of cases stained.
Oligomeric tau and pThr231 staining
Rabbit anti T22 (EMD Millipore CA, USA) and rabbit anti
tau pThr231 (Thermo Fischer) were used to probe tau in-
clusions for the presence of oligomeric tau (T22) and for
phosphorylation at Thr231. Tau oligomeric species are cur-
rently hypothesized to be more toxic to neurons than the
fibrillar inclusions themselves [23], and pThr231 is thought
to be a key site in the regulation of tau protein folding and
ability to interact with microtubules [3, 24]. Double label-
ing was performed on hippocampus from one case each
from AD, ALSci, FTD, MSA, DLDB, and mDLDB. Tau
protein was probed for pThr175 using rabbit primary anti-
body (1:1000) overnight at 4 °C and Alexa Fluor goat anti-
rabbit 488 nm secondary (1:200, Thermo Fischer) for 1 h
at room temperature. Rabbit anti tau pThr231 antibody
was then labeled using a Zenon primary antibody labeling
kit with Alexa Fluor 555 nm dye (Thermo Fisher) and
probed for 1 h at room temperature. Slides were stored
overnight at 4 °C and visualized within 24 h of labeling by





ALS Consistent with our earlier reports, we observed
tau pathology in multiple brain regions in ALS, although
to a lesser degree than either ALSci or the remaining
tauopathies. Neuronal tau inclusions were most consist-
ently observed in the entorhinal cortex, hippocampus,
and amygdala. All antibodies were immunoreactive with
neuronal tau inclusions in multiple brain regions
(Table 3). Frontal and anterior cingulate pathology was
limited in both load and case-positive incidence. In all
regions studied, inclusions took the form of punctate
cytosolic inclusions or tangles (Fig. 1). Deposition was
mainly restricted to the superficial cortical layers in the
entorhinal cortex but restricted to deeper layers in the
ACC and superior frontal cortex when present.
ALSci Tau pathology (Fig. 1, Additional file 1: Figure S1,
Additional file 2: Figure S2, Additional file 3: Figure S3)
in the form of tangles, skein-like inclusions, and punc-
tate staining was observed to a greater extent in ALSci
than ALS, especially in the ACC and superior frontal
cortex. The load of pathology was increased in amount
and distribution and the case positive ratio was higher
than ALS in all brain regions studied (Table 4). As ob-
served in ALS, pathological tau neuronal inclusions were
observed predominantly in the superficial layers of the
entorhinal cortex and within deeper cortical layers in the
ACC and superior frontal cortex. However superficial
layer involvement was noted in both the ACC and su-
perior frontal cortex in ALSci, indicating a greater distri-
bution across cortical layers in ACC and frontal cortex,
further differentiating ALSci from ALS. Of note, Thr175
tau and PHF tau identified pathology to different extents
in different brain regions. Notably, pThr175 tau and
pThr217 tau identified a higher case positive ratio than
PHF in the superior frontal cortex.
Tauopathies Within the tauopathies and consistent with
the literature, we observed tau neuronal pathology
across multiple regions (Table 5). pThr175 tau was
present in all disease states where tau pathology was
prominent. In Alzheimer’s disease (AD), all tau anti-
bodies showed robust neuronal pathology as neurofibril-
lary tangles and punctate cytoplasmic inclusions in all
Table 2 Antibodies
Antibody Clone Titre Antigen retrieval Epitope Company
Tau pThr175 Rabbit, polyclonal 1:1000 1 pThr175 21st Century
Tau pThr217 Rabbit, polyclonal 1:1000 1 pThr217 21st Century
Tau pSer208, 210 Rabbit, polyclonal 1:1000 1 pSer208, 210 21st Century
PHF (AT8) Mouse, monoclonal 2.5 ug/ml No pSer202 Thermo Fischer
Tau pThr231 Rabbit, polyclonal 1:1000 2 pThr231 Thermo Fischer
T22 Rabbit, polyclonal 1:500 2 Tau oligomer EMD Millipore
Alexa Fluor 488 Goat anti-rabbit 1:200 2 Secondary Life Technologies
1) Boil in 10 mM sodium citrate, 0.05% Tween 20 pH 6.0 for 2 min
2) Pressure cooker (2100 Retriever; Aptum Biologics, UK) 10 mM sodium citrate, 0.05% Tween 20 pH 6.0 for 15 min
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brain regions studied. Across all cortical regions studied,
neuronal pathology was present across all cortical layers
but was most prominent in deeper layers (IV-VI).
Amongst the tauopathies, the most prominent pThr175
tau immunostaining was observed in AD. This included
more prominent expression of pThr175 tau than ob-
served in ALSci.
As in AD, VD exhibited tau protein deposition as tangles
and punctate cytoplasmic inclusions in all brain regions
studied. This followed the same trend as AD with path-
ology being most prominent in deep cortical layers. In
CBD, balloon neurons were observed and tau pathology
was prominent in all brain regions as punctate inclu-
sions and neurofibrillary tangles. Notably, PHF tau stain-
ing was more intense than pThr175 tau in all regions,
both in case positive ratio and in semiquantitative patho-
logical load. In both DLBD and mDLBD, a similar de-
gree of tau pathology was observed in the form of
cytoplasmic punctate deposition and neurofibrillary tan-
gles. Pathology within the dentate gyrus, basal ganglia
and substantia nigra was present to a much greater ex-
tent in mDLBD than DLBD. In FTLD, tau pathology was
observed as punctate inclusions and tangles in all brain
regions investigated. In general, pThr175 tau was less
prominent than PHF tau, except in the frontal and cin-
gulate cortex where it was more prominent on a case
positive basis and the pathological load observed. In
MSA, tau pathology in the form of tangles and punctate
inclusions was present in all brain regions studied al-
though frontal and ACC pathology was sparse. In Par-
kinson’s disease, tau pathology was observed in all brain
regions except the substantia nigra. Pathological tau ex-
pression was equivalent across all antibodies. In Pick’s
disease, all brain regions investigated exhibited tau path-
ology in the form of tangles, punctate inclusions and
Pick bodies. Notably, PHF tau pathology was greater
than the other antibodies including pThr175 tau.
Neuritic tau
ALS No neuritic plaques were observed in ALS. Neuritic
pathology in the form of dystrophic neurites was ob-
served to a limited extent in all brain regions studied
and with a pattern of distribution mimicking that de-
scribed above for neuronal pathology. Basal ganglia
neuritic pathology was observed to a larger extent in the
putamen than the globus pallidus by all tau antibodies
but pThr175 tau. Neuritic tau pathology within the sub-
stantia nigra was immunoreactive against all antibodies
employed in the analysis.
ALSci Neuritic tau pathology was observed predomin-
antly as dystrophic neurites assuming a short curvilinear
morphology. This was consistently observed in both cor-
tical and subcortical tissues. Contrary to the superficial
localization of frontal and ACC neuronal pathology,
frontal neuritic pathology was observed mainly in deep
layers as short curved neurites. Entorhinal neuritic path-
ology was observed mainly in the superficial layers in
proximity to tau inclusion bearing neurons. Neuritic pla-
ques were observed in the entorhinal cortex by all anti-
bodies with the exception of the pThr175 tau antibody.
Neuritic plaques within the amygdala were observed by
PHF tau antibody labeling only. Neuritic plaques and tau
positive neurites were observed in the hippocampus and
Table 3 ALS pathology
Stain Frontal Cingulate Hippocampus Dentate Entorhinal Amygdala BG SN
Neuronal
pThr175 ± (1/5) ± (1/4) ± (1/5) ± (1/5) ± (2/4) ++ (1/2) - (0/5) - (0/5)
PHF ± (1/5) ± (1/4) ± (3/5) ± (2/5) ± − ++ (5/5) +++ (1/1) ± (1/4) ± (3/4)
pSer208,210 - (0/5) ++ (1/4) ± (1/5) - (0/4) ± (1/2) ++ (1/2) - (0/5) - (0/5)
pThr217 + (1/5) ± (1/4) ± (1/5) - (0/4) ± − ++ (3/4) ++ (1/2) ± (1/4) ± (2/5)
Glial
pThr175 ++ (1/5) - (0/5) - (0/4) - (0/5) - (0/2) ± (1/2) + (1/5) - (0/5)
PHF ± (1/5) ± (1/4) ± (1/5) - (0/5) + (1/5) ++ (1/1) - (0/4) - (0/4)
pSer208,210 - (0/5) - (0/4) - (0/5) - (0/4) ± (1/2) ++ (1/2) ++ (2/5) - (0/5)
pThr217 +++ (1/5) +++ (1/4) + (1/5) - (0/4) +++ (1/4) ++ (1/2) ++ (2/4) - (0/5)
Neuritic
pThr175 - (0/5) - (0/5) ± (1/4) - (0/4) ± (2/5) ++ (1/2) - (0/5) ± (1/5)
PHF ± (2/5) ± (1/4) ± (3/5) - (0/5) + − ++ (5/5) ++ (1/1) ± (1/4) ± (3/4)
pSer208,210 - (0/5) ± (1/4) - (0/5) - (0/4) ± (1/2) - (0/2) + (1/5) + (2/5)
pThr217 ± (1/5) - (0/4) ± (1/5) - (0/4) ± − ++ (3/4) ± (1/2) + − ++ (2/4) + − ++ (3/5)
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were immunoreactive to all antibodies. Coiled bodies
were observed throughout the basal ganglia.
Tauopathies Neuritic pathology was prominent across
all the tauopathies and typically mirrored the presence
of tau immunoreactive neuronal pathology. Neuritic
plaques were observed in AD as small atypical plaques
and typical plaques in deeper layers (IV/V) more fre-
quently than in superficial layers (II/III). No antibody
identified neuritic plaques in basal ganglia or substan-
tia nigra. Like neuronal tau, all cortical neuritic path-
ology was most prominent in deeper layers (IV-VI).
All antibodies recognized neuritic pathology, most
commonly in deeper cortical layers near tau positive
neurons as short and curved, or long, straight neur-
ites. Neuritic pathology was also observed to a lesser
extent in white matter in frontal, ACC, and entorhinal
cortices.
Fig. 1 Representative pThr175 tau pathology in each neurodegenerative disease. a AD Frontal cortex, b ALS amygdala, c ALSci amygdala, d ALSci
hippocampus neuritic plaque, e CBD entorhinal cortex, f DLBD amygdala, g mDLBD entorhinal cortex, h FTLD putamen, i MSA amygdala, j PD
amygdala, k Pick’s entorhinal cortex, l VD anterior cingulate cortex. Nuclear fast red or hematoxylin counterstain used. Original images taken at 100×
Moszczynski et al. Acta Neuropathologica Communications  (2017) 5:6 Page 5 of 14
Similar to AD, neuritic pathology in VD was present as
tau positive neurites and neuritic plaques in all brain re-
gions studied except the substantia nigra. Also similar to
AD, neuritic pathology followed a tendancy to be most
pronounced in regions of prominent neuronal tau path-
ology and in particular in the deeper cortical layers. In
CBD, neuritic plaques were only observed in the ACC
and substantia nigra, and then, only using the PHF tau
antibody. Neuritic pathology, as dystrophic neurites, was
present in all brain regions investigated and mirrored
the distribution of neuronal pathology. This was most
evident in the entorhinal cortices where dystrophic neur-
ites were most evident in superficial cortical layers. In
contrast, dystrophic neurites were most prominent in
deep subcortical regions of the superior frontal cortex
and ACC.
In DLBD, no frontal, ACC, dentate gyrus or basal ganglia
neuritic pathology was observed. All other regions studied
were positive for neuritic tau pathology, but no plaques
were observed. Entorhinal neuritic pathology was most
prominent in DLDB in layers II/III. In mDLBD, neuritic
plaques were observed in all regions except for the substan-
tia nigra. All regions studied exhibited neuritic pathology.
In both FTLD and MSA, neuritic plaque pathology was not
frequent and usually observed by PHF tau only. pThr175 tau
neuritic pathology was not as prominent as that observed
using other tau antibodies. However, neuritic tau pathology
was observed in all brain regions studied as with neuronal
pathology. In PD, neuritic plaques were not observed, but
tau positive neurites were observed in a similar distribution
to neuronal pathology in all brain regions studied. In Pick’s
disease, neuritic pathology was identified mainly by PHF
tau in all but the dentate gyrus.
Glial tau
ALS Glial tau pathology was observed in all brain re-
gions except the dentate gyrus, and substantia nigra
(Table 3). Where present, glial pathology presented as
glial fibrillary tangles and astrocytic plaques as previ-
ously described [12]. The distribution was sparse and
followed that of neuronal and neuritic tau as described
above and was similar in case positive ratio, although
higher in semiquantitative load than neuronal and neur-
itic pathology in a single case.
ALSci Glial pathology was present in ALSci (Fig. 1,
Additional file 1: Figure S1, Additional file 2: Figure S2,
Additional file 3: Figure S3) to a similar degree as in
ALS, but was more frequent in terms of regional distri-
bution, case positive rate, and pathological load (Table 4).
Frontal and ACC glial pathology was increased in both
case positive incidence and pathological load.
Tauopathies In the tauopathies, the extent of glial
pathology was highly dependant on the underlying
disease (Table 5). In AD, glial pathology was rare, and
when present was usually observed only in the amyg-
dala and basal ganglia. No glial pathology was ob-
served in VD. Consistent with the literature, CBD
contained astrocytic plaques throughout the grey and
white matter across multiple brain regions. Additional
astrocytic staining and tau positive microglia were ob-
served. Glial pathology in CBD was identified to a far
greater extent by PHF tau than the pThr175 tau anti-
body. In DLBD, minimal glial pathology was observed
in frontal cortex and basal ganglia, and when present,
Table 4 ALSci pathology
Stain Frontal Cingulate Hippocampus Dentate Entorhinal Amygdala BG SN
Neuronal
pThr175 ± (4/5) ± (2/5) ± (5/5) + (1/5) + (4/4) + (1/1) - (0/5) - (0/3)
PHF + (2/4) ± (3/3) ± − + (4/4) ± − + (2/4) ± − ++ (4/4) ± − ++ (2/2) - (0/5) ± (2/2)
pSer208,210 ± (2/5) ± (3/5) ± − ++ (4/5) ± (1/5) ± − ++ (3/4) + (1/1) - (0/5) - (0/3)
pThr217 ± (5/5) ± − + (3/5) ± − ++ (5/5) ± − ++ (3/5) ± − ++ (5/5) + (1/1) - (0/5) ± − + (2/2)
Glial
pThr175 ± − ++ (2/5) ± − ++ (2/5) - (0/5) - (0/5) ± (1/4) - (0/1) ± − + (2/5) - (0/3)
PHF ± − ++ (4/4) ± − ++ (2/3) - (0/4) - (0/4) - (0/4) + (1/2) ± (3/5) - (0/2)
pSer208,210 ++ (4/5) ++ (2/5) - (0/5) - (0/5) ± (1/4) - (0/1) ± − + (4/5) ± (1/3)
pThr217 ++ − +++ (5/5) +++ (2/5) ++ (2/5) - (0/5) ± (1/5) - (0/1) + − ++ (5/5) - (0/2)
Neuritic
pThr175 ± − + (3/5) ± − + (2/5) ± − + (3/5) ± − ++ (4/5) ± − ++ (4/4) - (0/1) ± (4/5) ± (1/3)
PHF ± − + (2/4) ± − + (3/3) ± − + (3/4) ± (3/4) ± − ++ (4/4) ± − ++ (2/2) ± (2/5) ± (2/2)
pSer208,210 ± − + (2/5) ± (3/5) ± (4/5) ± (2/5) ± − ++ (4/5) + (1/1) ± (1/5) ± (1/3)
pThr217 ± − ++ (5/5) ± − ++ (2/5) ± − + (4/5) ++ (2/5) + − +++ (5/5) + (1/1) ± (3/5) ± − ++ (2/2)
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only as punctate astrocytic inclusions. In contrast to
the limited glial pathology observed in DLBD,
mDLBD showed much more frequent glial pathology
across multiple brain regions, pathology that was less
evident with the pThr175 tau antibody. In FTLD, glial
pathology was observed in all brain regions except
the dentate gyrus and substantia nigra. Notable in this
disease, pThr175 tau identified glial pathology to a
greater extent than PHF tau by both case positive in-
cidence and increased load. In MSA, glial pathology
was largely absent, being present only in the entorhi-
nal cortex, amygdala and basal ganglia by multiple
antibodies. Interestingly, the basal ganglia contained
astrocytic inclusions in the putamen identified by all
antibodies whereas in the globus pallidus they were
only identified by pThr175 tau. In Parkinson’s disease,
glial pathology was present in all regions except the
dentate gyrus and substantia nigra. Notably, the PHF
tau antibody identified astrocytic plaques in the
frontal cortex while tufted astrocytes were observed
in the amygdala. In Pick’s disease, glial pathology was
observed in multiple brain regions using the PHF
antibody mainly, although in the entorhinal cortex
pThr175 tau was also positive for glial pathology.
pThr231 tau and T22 staining
We examined the presence of oligomeric tau (recognized
by the T22 antibody) and pathological tau phosphoryl-
ation at Thr231 using sections from the hippocampus of a
single case each of AD, ALSci, FTD, MSA, DLBD, and
mDLB. Cases were selected on the basis of the pathology
described earlier. In each case, tau neuronal inclusions
were recognized by both antibodies (Figs. 2 and 3). Only
DLBD showed notably reduced T22 pathology which,
when present, was in the dystrophic neurites (Fig. 3). Glial
pathology was not observed with either antibody, regard-
less of diagnosis.
AD neuronal pathology was observed as fibrillar and
punctate inclusions by pThr231 tau antibody but only as
fibrillar/tangles with T22. Neuritic pathology in the form
of short and long torsional and dystrophic neurites was
observed. pThr231 tau, but not T22, recognized plaques
consisting of dystrophic neurites.
Fig. 2 Representative hippocampal pThr231 tau pathology. a AD, b ALSci, c DLBD, d mDLBD, e FTLD, f MSA. Counterstained with hematoxylin.
Original images taken at 100×
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Similar to AD, ALSci neuronal pathology was observed
by pThr231 tau and T22 as fibrillar and punctate stain-
ing. However additional solitary cytoplasmic inclusions
were observed in neurons with the T22 antibody. Neur-
itic pathology was observed using both the pThr231 tau
and T22 antibodies. Neuritic plaques were identified by
both the pThr231 tau and T22 antibodies.
FTLD pathology was distinct from AD and ALSci in that
pThr231 tau neuronal pathology was observed as a dense
nuclear ring staining around abnormally folded nuclei, and
solitary cytosolic inclusions on homogenously stained cyto-
sol. While T22 neuronal cytoplasmic pathology was ob-
served, neuritic pathology was observed as frequent short
dystrophic neurites by both antibodies. No neuritic plaques
were observed.
MSA pathology resembled AD and ALSci. Neuronal
pathology was observed as tangles and punctate inclusions
by both the pThr231 tau and T22 antibodies. In addition,
pThr231 tau antibody diffuse cytoplasmic immunostaining
was observed. Neuritic pathology was observed by both
antibodies, although T22 immunoreactive neurites demon-
strated a punctate staining pattern.
DLBD tau pathology was observed only faintly by
pThr231 tau as punctate cytosolic deposition. While
neuritic pathology was observed using the pThr231
tau antibody, no pathology was observed by T22
other than a few sporadic neurites. Conversely,
mDLBD pathology was observed by both pThr231 tau
and T22. pThr231 tau pathology was observed as tan-
gles and punctate staining accompanied by dys-
trophic neurites and other neuritic pathology. No
neuritic plaques were observed. T22 pathology how-
ever was observed as punctate cytosolic staining and
dystrophic neurites.
Having confirmed that both T22 and pThr231 tau im-
munoreactive pathology was present, although as de-
scribed to varying degrees, we next sought to confirm
whether pThr175 tau and pThr231 tau co-localized using
confocal imaging (Fig. 4). Colocalization within neuronal
tau inclusions was observed between pThr175 tau and
pThr231 tau in each disease state except for DLBD. Colo-
calization was also observed in neuritic plaques in AD.
No pThr175 tau immunoreactivity was observed in the
absence of pThr231.
Fig. 3 Representative hippocampal tau oligomer (T22) pathology. a AD, b ALSci, c DLBD, d mDLBD (e) FTLD (f) MSA. Counterstained with
hematoxylin. Original images taken at 100×
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Hippocampal pThr175, pThr231 and oligomeric tau
deposition as a function of aging
Consistent with our previous report, we observed an in-
crease in tau-immunoreactive pathology beginning in
the 7th decade of life [22]. In contrast, no immunoreac-
tive inclusions were observed to either the pThr175 tau
or oligomeric tau (T22 immunoreactivity) in the 6th dec-
ade (Fig. 5). pThr231 tau immunoreactivity was observed
in each of the 6th, 7th and 8th decades within the hippo-
campus. In distinction to the pathological tau deposition
observed in both ALSci and the tauopathies, neuronal
Thr231 tau immunoreactivity was diffuse and localized to
otherwise healthy appearing neurons and axonal pro-
cesses. In the 7th decade, T22 immunoreactive neuronal
cytoplasmic inclusions were observed minimally and
when present were within the same regions in which we
observed punctate pThr175 immunoreactivity. All but
one case demonstrated pThr231 tau immunoreactivity,
and importantly this case was negative for all three tau
epitopes. In all cases, neuritic pathology was minimal or
Fig. 4 Co-localization of pThr175 and pThr231 tau in hippocampal neuronal inclusions. AD: Alzheimer’s disease. ALSci: amyotrophic lateral sclerosis
with cognitive impairment. FTLD: frontotemporal lobar dementia. mDLBD: mixed diffuse dementia with Lewy bodies. MSA: Multiple system
atrophy. Scale bar represents 5 μm
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nonexistent, while neuronal positivity was mainly punc-
tate tau expression.
In the 8th decade, we observed a marked increase in
pThr175 tau, pThr231 tau and T22 immunoreactivity. In
this decade, each antibody revealed tau immunoreactive
punctate staining of neurons, neurofibrillary tangles, dys-
trophic neurites, and neuritic plaques. Across all three de-
cades, T22 pathology was present in all cases and in
regions where pThr231 tau and pThr175 tau was present,
and was only positive in cases with prominent pThr175 tau
positive cells and pathology.
Discussion
In undertaking these studies, we were specifically interested
in determining whether the pathogenic phospho-tau spe-
cies recognized by antibodies against pThr175 tau and
pThr231 tau as well as oligomeric tau (T22) were expressed
across a broad range of tauopathies. We were also inter-
ested in determining whether these pathological tau species
were colocalized in ALS and ALSci. It is known that the
phosphorylation of tau protein at Thr231 is of both physio-
logical and pathological significance in mediating the dis-
sociation of tau from microtubules [3, 24, 25]. Thr231 is
phosphorylated by activated GSK3β physiologically and in
pathological states [25–29]. We have previously shown that
pThr175 tau induces GSK3β phosphorylation and that this
in turn leads to Thr231 tau phosphorylation resulting in tau
fibril formation and cell death in vitro [17].
Although the number of cases studied here is limited,
the intent was not to undertake a detailed topographic
analysis of tau deposition across all tauopathies, but ra-
ther to determine whether the proposed pathway of
pThr175 tau mediated induction of pThr231 tau forma-
tion with its attendant pathological tau fibril formation
(as recognized by T22) was evident. It is noteworthy
therefore that we observed that in each tauopathy stud-
ied, pThr175 tau, pThr231 tau and T22 immunoreactivity
co-localized to the same inclusion-containing neuronal
populations. In each case, neuronal pThr175 tau coloca-
lized with pThr231 tau. This, paired with the prior identi-
fication of pThr175 tau in AD brain tissue but not
controls [30] and the lack of identified pThr175 in fetal
tau [15, 16] suggests that pThr175 is a key point in
pathological tau metabolism, as it is not a physiologically
utilized site involved in the regulation of tau function
during development or microtubule reorganization. This
suggests that the downstream events triggered by
pThr175 tau, including toxic monomer formation, are
common to each of these diseases.
To further assess the pathogenicity of pThr175 and
pThr231, we investigated each epitope in the hippocam-
pus of control cases across three decades of life where
tau pathology has been shown to increase with age [22].
We observed no pThr175 tau pathology in the 6th decade
with minimal immunoreactive neuronal inclusions in the
7th decade. pThr175 tau immunoreactivity was most
Fig. 5 Age dependent tau pathology increases in the hippocampus of controls and is associated with pThr175 tau pathology in the 8th decade of
life. Large images taken in the CA2 region of the hippocampus at 10× magnification, inset is same region at 40× magnification
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prominent in the 8th decade. In each case in which we
observed pThr175 tau immunostaining, we also observed
T22 immunoreactivity. Similarly, we never observed T22
immunoreactivity in the absence of either pThr175 tau or
pThr231 tau immunoreactivity. In contrast, pThr231 tau
immunoreactivity was frequently observed in the ab-
sence of either pThr175 tau or T22 staining in younger
individuals and when present, was within healthy
appearing neurons and axonal processes. pThr175 and
T22 did not show pathology in hippocampal regions
spared from pThr231 pathology, and T22 was only posi-
tive in cases showing prominent pThr175 pathology.
Glial pathology was recognized to a greater degree by
pThr217 tau and PHF tau than by the pThr175 tau anti-
body, suggesting that different pathological processes are
at play in these cells. This is supported by the lack of
identifiable glial pathology by pThr231 tau and T22. This
paired with the low frequency of pThr175 tau glial path-
ology further strengthens the correlation between
pThr175 and pThr231 in the induction of neuronal path-
ology and provides evidence that this pair of phosphoryl-
ation sites may be exerting specific neuronal toxicity in
the disease process across multiple tauopathies.
Although limbic regions universally presented tau
pathology, frontal and ACC tau pathology was present
mainly in AD, VD, ALSci, FTLD, mDLBD and MSA.
This paired with the deeper layer pathology in this re-
gion may indicate that tau pathology did not originate
here but instead propagated from other regions. If tau
originates in limbic structures, propagating along the
Papez circuit, it is possible that it would arrive in ACC
through thalamic projections to layer IV and V which
could act as a hub for propagation to other brain re-
gions such as frontal cortex through this well con-
nected region. Regardless of the induction cause or
place, tau protein toxicity is undeniable once initiated
[23, 31], and must be considered when attempting to
understand the underlying biology of many neurode-
generative diseases. This hypothesis also implies that
disease entities such as primary age-related tauopa-
thies (PART) [32] may be in fact not age-related, but
neuronal stress related, as increasing age would indi-
cate longer time periods for stresses on neurons to be-
come pathological through stochastic processes [33].
Therefore, tau protein deposition should not be con-
sidered a simple function of normal ageing, but ageing
should be considered a risk factor for tauopathy
among a plethora of neuronal stresses. Of note as well
is the frontal involvement in ALSci, which can be con-
cluded is not likely a result of PART, which spares the
neocortex by definition [22, 32]. We cannot conclude,
however if the layer distribution of tau pathology re-
sembles PART, as this was not described in the con-
sensus report.
Conclusions
These findings implicate a toxic axis of phosphorylation
events beginning with Thr175 phosphorylation, dependent
on further phosphorylation at Thr231, which appears to be
neuron specific and which may be common to the tauopa-
thies. The extent to which this process is reflective of not
only the presence of a tauopathy, but the disease load as
would be encapsulated in the “ABC” score will require
much greater case numbers across each disease state. In
this paper, we simply raise the critical question that this
pathway of pathological tau phosphorylation may be a con-
tributor to neuronal death in these diseases, and thus a
point of intervention capable of slowing disease progression
resulting from tau protein toxicity.
Additional files
Additional file 1: Figure S1. Representative PHF tau pathology in each
neurodegenerative disease. A) AD hippocampus, B) ALS amygdala, C)
ALSci superior frontal cortex, D) ALSci superior frontal cortex astrocytic
tau E) CBD entorhinal cortex, F) DLBD amygdala, G) mDLBD entorhinal
cortex, H) FTLD entorhinal cortex, I) MSA amygdala, J) PD entorhinal
cortex, K) Pick’s amygdala, L) VD anterior cingulate cortex. Nuclear fast
red or hematoxylin counterstain used. Original images taken at 100×. (TIF
30305 kb)
Additional file 2: Figure S2. Representative pSer208,210 tau pathology in
each neurodegenerative disease. A) AD substantia nigra, B) ALS
amygdala, C) ALSci entorhinal cortax, D) ALSci ACC neuritic plaque, E)
CBD entorhinal cortex, F) DLBD entorhinal cortex, G) mDLBD amygdala,
H) FTLD superior frontal cortex, I) MSA amygdala, J) PD entorhinal cortex,
K) Pick’s entorhinal cortex, L) VD superior frontal cortex. Nuclear fast red
or hematoxylin counterstain used. Original images taken at 100×. (TIF
30111 kb)
Additional file 3: Figure S3. Representative pThr217 tau pathology in
each neurodegenerative disease. A) AD anterior cingulate cortex, B) ALS
entorhinal cortex, C) ALSci hippocampus, D) ALSci superior frontal cortex
astrocytic plaque, E) CBD entorhinal cortex, F) DLBD hippocampus, G)
mDLBD amygdala, H) FTLD amygdala, I) MSA amygdala, J) PD entorhinal
cortex, K) Pick’s entorhinal cortex, L) VD entorhinal cortex. Nuclear fast red
or hematoxylin counterstain used. Original images taken at 100×. (TIF
30702 kb)
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